These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 25667500)
1. Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG). Linardou H; Pentheroudakis G; Varthalitis I; Gogas H; Pectasides D; Makatsoris T; Fountzilas G; Bafaloukos D; Anticancer Res; 2015 Feb; 35(2):1105-13. PubMed ID: 25667500 [TBL] [Abstract][Full Text] [Related]
2. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944 [TBL] [Abstract][Full Text] [Related]
3. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Bafaloukos D; Tsoutsos D; Kalofonos H; Chalkidou S; Panagiotou P; Linardou E; Briassoulis E; Efstathiou E; Polyzos A; Fountzilas G; Christodoulou C; Kouroussis C; Iconomou T; Gogas H Ann Oncol; 2005 Jun; 16(6):950-7. PubMed ID: 15829494 [TBL] [Abstract][Full Text] [Related]
4. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. Christodoulou C; Bafaloukos D; Linardou H; Aravantinos G; Bamias A; Carina M; Klouvas G; Skarlos D; J Neurooncol; 2005 Jan; 71(1):61-5. PubMed ID: 15719277 [TBL] [Abstract][Full Text] [Related]
5. Temozolomide and cisplatin in avdanced malignant melanoma. Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103 [TBL] [Abstract][Full Text] [Related]
6. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674 [TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172 [TBL] [Abstract][Full Text] [Related]
10. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). von Moos R; Seifert B; Simcock M; Goldinger SM; Gillessen S; Ochsenbein A; Michielin O; Cathomas R; Schläppi M; Moch H; Schraml PH; Mjhic-Probst D; Mamot C; Schönewolf N; Dummer R; Ann Oncol; 2012 Feb; 23(2):531-6. PubMed ID: 21527587 [TBL] [Abstract][Full Text] [Related]
11. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989 [TBL] [Abstract][Full Text] [Related]
13. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005 [TBL] [Abstract][Full Text] [Related]
14. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061 [TBL] [Abstract][Full Text] [Related]
15. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595 [TBL] [Abstract][Full Text] [Related]
16. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. Kaufmann R; Spieth K; Leiter U; Mauch C; von den Driesch P; Vogt T; Linse R; Tilgen W; Schadendorf D; Becker JC; Sebastian G; Krengel S; Kretschmer L; Garbe C; Dummer R; J Clin Oncol; 2005 Dec; 23(35):9001-7. PubMed ID: 16260697 [TBL] [Abstract][Full Text] [Related]
17. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943 [TBL] [Abstract][Full Text] [Related]
18. Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. Wierzbicka-Hainaut E; Sassolas B; Mourey L; Guillot B; Bedane C; Guillet G; Tourani JM Melanoma Res; 2010 Apr; 20(2):141-6. PubMed ID: 20075758 [TBL] [Abstract][Full Text] [Related]
19. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457 [TBL] [Abstract][Full Text] [Related]
20. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]